The complex relationship between left atrial (LA) structure and function, electrical burden of atrial fibrillation (AF) and stroke risk is not well understood. We aimed to describe LA structure and function in AF.
Introduction
Atrial fibrillation (AF) is common, increasing in frequency, and is associated with an elevated risk for stroke and death. 1 Recent therapeutic advances, including new oral anticoagulant agents and ablation techniques, provide significant improvement in the care of AF patients. 2, 3 However, identifying patients who are most and least likely to benefit from these therapies remains challenging even with current risk prediction tools. 1 Understanding the relationship between cardiac structure and function, electrical burden, and stroke risk in AF may help refine patient selection for anticoagulation and/or rhythm control strategies. However, prior echocardiographic studies have yielded conflicting results regarding the association between cardiac structure, function, and stroke risk in AF. 4 -7 These studies primarily evaluated left atrial (LA) size, while increasing attention is now being given to LA function. 8 -10 Therefore, we evaluated LA size and function, according to the electrical burden of AF (paroxysmal, persistent, and permanent) as well as stroke risk expressed in the CHADS 2 score (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke/TIA) in subjects enrolled in the Effective aNticoaGulation with factor xA next GEneration in AF-Thrombolysis In Myocardial Infarction 48 (ENGAGE AF-TIMI 48) study.
Methods

Study population
ENGAGE AF-TIMI 48 is a multinational, randomized (1:1:1), doubleblind, double-dummy non-inferiority design trial comparing the efficacy and safety of two dosing regimens of edoxaban (high and low dose with dose reductions for patients at a high risk of bleeding) vs. warfarin titrated to an INR of 2.0 -3.0 in subjects with a history of AF. The study included AF subjects at moderate-to-high risk for thrombo-embolic events (CHADS 2 score ≥2). Inclusion and exclusion criteria have been previously described. 11 Briefly, eligible subjects were men or women ≥21 years old with a history of AF of any duration documented by an electrocardiogram within the prior 12 months and in whom anticoagulation was indicated. Key exclusion criteria were: AF due to reversible causes, severe renal dysfunction (creatinine clearance ,30 mL/min), high-bleeding risk, and/or moderate-or-severe mitral stenosis. Randomization was stratified by the CHADS 2 risk score 2-3 vs. [4] [5] [6] , and factors requiring a reduced dose of edoxaban. The study protocol complied with the Declaration of Helsinki and was approved by institutional review boards at each site. Written informed consent was obtained in all patients.
The prospectively designed echocardiographic substudy of ENGAGE AF-TIMI 48 was performed at 133 sites worldwide between 2009 and 2011. Subjects were invited prior to randomization to voluntarily participate with echocardiographic imaging obtained within the first week after randomization. Sonographers underwent training in the details of the echocardiographic views and techniques and received a detailed procedure manual. Standard 2D and Doppler transthoracic echocardiography was performed with images sent to the echocardiography core laboratory at Brigham and Women's Hospital, Boston, MA, USA. Conventional echocardiographic analyses were performed according to previously described methods by technicians blinded to clinical information and treatment assignment, with all study measurements confirmed by a board certified cardiologist and echocardiographer. 
Echocardiographic analyses
Echocardiographic quantification was performed according to American Society of Echocardiography guidelines. 13 Left atrial diameter was the 2D anterior -posterior length in the parasternal long-axis view. Left atrial maximum volume was measured by the modified Simpson's method using apical four-and two-chamber views at the end-systolic frame preceding mitral valve opening, and was indexed to the body surface area to derive the LA volume index (LAVI). Similarly, LA minimum volume was measured at the end-diastolic frame preceding mitral valve closure, while LA pre A volume was measured at the onset of the electrocardiographic P-wave for subjects not in AF at the time of echocardiography (Supplementary material online, Figure S1 ). Final values were taken as the mean of measurements from three cardiac cycles. Atrial fibrillation at the time of echocardiography was determined by the absence of A-waves on transmitral spectral Doppler flow and tissue Doppler mitral annular velocity profiles, as well as the lack of organized electrocardiographic P-waves. The reproducibility of measurements of LA volumes has been evaluated in the echocardiographic core lab at Brigham and Women's Hospital in 20 subjects: intra-observer intraclass correlation coefficient 0.95 (0.91-0.99) and inter-observer intraclass correlation coefficient 0.84 (0.75 -0.93).
Statistical methods
Subjects' electrical burden of AF was classified according to type of AF: paroxysmal, persistent, or permanent, defined in accordance with AHA/ACC/ESC guidelines 18 and as determined by the site investigator. Left atrial structure and function in atrial fibrillation AF were made with Cuzick's non-parametric trend test. 19 Multivariateordered logistic regression was used to assess for the relationship between cardiac structure and function and CHADS 2 risk score, with adjustment for heart rate, blood pressure, and rhythm at the time of echocardiography. Forward stepwise multivariate-ordered logistic regression was used to identify features of cardiac structure and function significantly associated with higher CHADS 2 scores. As echocardiograms were obtained within 1 week after randomization and this is a cross-sectional analysis, treatment allocation to edoxaban or warfarin was not included. All analyses were performed using Stata 11.2 (Stata Corp., College Station, TX, USA) with P-values ,0.05 considered statistically significant. No adjustments were made for multiple comparisons.
Results
Overall study population
The ENGAGE AF-TIMI 48 echocardiographic substudy enrolled 1120 subjects, of whom 971 (87%) had technically adequate images. These results were obtained prior to the unblinding of subject's study drug allocation. When compared with the 971 subjects included in the echocardiographic analysis, the 149 subjects not included were slightly younger (median 71 vs. 73 years, P ¼ 0.020), had comparable CHADS 2 scores (median 3 in both groups), and the proportions with persistent or permanent AF were similar. When compared with the other 20 134 subjects in the parent ENGAGE AF-TIMI 48 trial, the 971 subjects included in the final echocardiographic analysis were older (median 73 vs. 72 years, P , 0.001), but were less likely to be female (34 vs. 38%, P ¼ 0.015), and more frequently Caucasian (92 vs. 80%, P , 0.001). Paroxysmal AF was more common in the echocardiographic cohort (33 vs. 25%, P , 0.001); while permanent AF was less frequent (46 vs. 52%, P ¼ 0.001). However, the CHADS 2 score was similar between the echocardiographic substudy and parent trial.
In the echocardiographic substudy, LA enlargement (defined as LAVI ≥29 mL/m
2 ) was present in nearly two-thirds of all subjects and there was a significant inverse relationship between LA function, measured by LAEF, and LAVI according to type of AF ( Figure 1A) . This relationship was similar when stratified by rhythm at the time echocardiography as well ( Figure 1B) . However, even among AF subjects with normal LAVI, approximately half had impaired LA EF. 
Paroxysmal, persistent, or permanent atrial fibrillation
Paroxysmal, persistent, and permanent AF were present in 33, 21, and 46% of subjects, respectively ( Table 1) . Approximately 25% of those with permanent AF had a CHADS 2 score of 4-6 compared with 18-19% of those with paroxysmal or persistent AF (P ¼ 0.09). Left atrial size, as determined by LAVIs, increased across AF types ( Figure 2A) with 48, 60, and 77% of paroxysmal, persistent, and permanent AF having enlarged LA, respectively ( Table 2) . Left atrial function, assessed by EF, significantly declined across the spectrum of AF types ( Figure 2B ). There was a corresponding decrease in LA compliance or reservoir function as assessed by the expansion index across AF types ( Figure 2C) . Left atrial conduit function, as determined by transmitral E-wave velocities, increased according to type of AF (Table 2 ). In the subset of subjects who were not in AF at the time of echocardiography, LA contractile function, determined by transmitral spectral Doppler A-wave velocities and mitral annular tissue Doppler a ′ velocities, declined with progression from paroxysmal to persistent to permanent AF ( Figure 2D ). Left ventricular and ejection fraction was preserved in most subjects (78%) regardless of AF type, although the prevalence of reduced LVEF (,50%) was twice as high in permanent when compared with paroxysmal AF. There was a corresponding trend towards a larger LV size and a higher LVMI in those with permanent AF, although the prevalence of abnormal LV geometry, defined as hypertrophy or concentric remodelling, did not differ. Left ventricular filling pressures (E/e ′ ) were also similar across groups ( Table 3 ). The frequency of reduced LVEF (,50%) was similar regardless of the CHADS 2 score ( Table 4) . Abnormal LV geometry increased in frequency with higher CHADS 2 scores. There was an inverse relationship between LV early diastolic relaxation (e ′ ) velocities and CHADS 2 score with a corresponding increase in LV filling pressures (E/e ′ ) across CHADS 2 categories. Similarly, LA size increased with higher CHADS 2 scores, with a parallel decline in LA EF. In forward stepwise multivariate-ordered logistic regression analyses, higher LV filling pressures (E/e ′ ), larger LAVI, and the presence of abnormal LV geometry were significantly associated with higher CHADS 2 score as a measure of stroke risk ( Table 5) . While both the burden of AF and the CHADS 2 score were related to LA size and function ( Figure 3A and B) , the electrical burden of AF appeared to be a stronger contributor than the CHADS 2 score. Lastly, as the CHA 2 DS 2 -VASc score 20 is a validated method for assessing stroke risk in AF, we also evaluated LA structure and function according to this system and found similar results as with CHADS 2 , namely that LAVI increased, LAEF decreased, and LA TDI A ′ velocities declined with a greater CHA 2 DS 2 -VASc score (Supplementary material online, Table S1 ).
Discussion
In a pre-specified echocardiographic substudy of the ENGAGE AF-TIMI 48 trial, we identified strong correlations between increasing abnormalities of LA structure and function with greater burdens of AF and higher CHADS 2 score, an estimate of stroke risk. While the majority of AF subjects had LA enlargement, we also demonstrated impaired LA function among a sizeable number of subjects with normal LA size. Furthermore, we found that LA contractile function was abnormal even in subjects in sinus rhythm. These findings suggest that the assessment of LA function may add important new information in the evaluation of the AF patient.
In an effort to improve stroke risk stratification beyond that achieved with conventional clinical characteristics, 21 others have explored the importance of LA size, but with mixed results in predicting stroke. 4 -7 While the majority of AF patients have enlarged LA, 4 -7 36% of AF subjects in this study had normal LA size, suggesting that a substantial number of AF patients are at moderate-to-high risk for stroke based on the CHADS 2 score despite normal LA size. Given the limitations of LA size, increasing attention has been given to LA function in AF. 8 We Data presented as counts (percentages) or median (inter-quartile ranges) for categorical and continuous variables, respectively. TIA, transient ischaemic attack; HD, heart disease; CKD, chronic kidney disease; BMI, body mass index. a CKD defined by creatinine clearance ,60 mL/min at randomization.
LA dysfunction may be at a higher risk for stroke despite normal LA size. This raises the possibility that the evaluation of LA function may be helpful in assessing stroke risk and in the identification of those who may benefit from anticoagulation strategies. 22 -24 Importantly, we also found that 17% of AF subjects had both normal LA size and function, which may not only represent a subgroup at a lower risk for stroke, but also patients most likely to respond to rhythm control strategies, 25 -28 although, these hypotheses remain to be formally tested in outcomes based studies. Several studies demonstrate a similar risk of stroke regardless of intermittent or sustained forms of AF, 29 -34 hence, current guidelines recommend anticoagulation regardless of whether AF is paroxysmal, persistent, or permanent. 18 However, these studies did not include evaluations of cardiac structure and function to potentially explain the clinical findings. In this study, we identified LA contractile dysfunction in the subset of subjects in sinus rhythm at the time of echocardiography, including those with paroxysmal AF, suggesting electro-mechanical dissociation. While previously described in the post-cardioversion period, 35 our findings suggest that electromechanical dissociation may be common in the broader AF population, including those with paroxysmal AF. 36 Left atrial contractile dysfunction among paroxysmal AF patients may not only help to explain the similar risk of stroke between intermittent and sustained forms of AF, but also raises the possibility that patients with abnormal LA contractile function may have a higher risk of stroke than those with normal contractile function. Additionally, we found that features of cardiac structure and function associated with a higher CHADS 2 score, including greater LV filling pressures and abnormal LV geometry, were similar across paroxysmal, persistent, and permanent AF. These results are consistent with proposed mechanisms for thrombus formation in AF, including stasis and endothelial dysfunction, 37 and are congruent with existing data from smaller studies. 23, 38, 39 Together, these findings may partially explain the previously reported similarities in stroke risk despite differing burdens of AF. However, whether these factors are of prognostic importance in the stratification of stroke risk needs to be prospectively tested. While we evaluated a relatively large contemporary AF population, limitations should be noted. The cross-sectional design precludes the assessment of causal relationships between cardiac structure and function and AF type. The irregular rhythm of AF may lead to beat-to-beat variability in echocardiographic measurements; however, our assessments were averaged over multiple cardiac cycles. Cardiac structure and function may differ between those in AF and those not in AF at the time of echocardiography, although we performed sensitivity analyses with stratification by rhythm at the time of echocardiography and the results did not substantially change (Supplementary material online, Table S2 ). Assessing LA deformation and function with strain imaging may provide additional information and is a future direction. While we cannot exclude misclassification bias with respect to AF type, as paroxysmal, persistent, and permanent designations were determined by site investigators, our results are largely consistent with registries of AF patients. 40, 41 By design, ENGAGE AF-TIMI 48 enrolled an AF population at moderate-to-high risk for stroke (CHADS 2 ≥2), therefore our assessment does not include the entire spectrum of CHADS 2 scores. Furthermore, we utilized CHADS 2 as a surrogate for stroke risk and therefore our findings need prospective evaluation in relation to clinical thrombo-embolic events.
In conclusion, we identified increasing abnormalities of LA structure and function with greater burdens of AF and stroke risk estimated by the CHADS 2 score. Moreover, we found that impairments in LA function were present even among subjects with normal LA size and sinus rhythm. These findings suggest that the assessment of LA function may add important incremental information to the evaluation of AF patients.
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